Oxagen Limited is a privately held biopharmaceutical company developing a pipeline of novel small molecule drugs to treat inflammatory and respiratory diseases. The company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and is progressing the most promising as drug targets. The lead program, targeting a GPCR known as CRTH2 with a strong genetic association to asthma, has generated a number of promising candidate small molecules which are orally bioavailable and offer the potential to treat asthma and other respiratory and inflammatory conditions.

Oxagen has an experienced management team with extensive combined experience in senior positions in top ten pharmaceutical companies. The team has proven ability in drug discovery and clinical development and is capable of prosecuting therapeutic targets from discovery to clinical studies across a range of therapeutic areas, but with particular expertise in inflammation and asthma. The company has driven its lead small molecule CRTH2 antagonist programme for asthma and allergic rhinoconjunctivitis from concept through 9 clinical trials and is currently in Phase IIb. In parallel the team has focused on building key external partnerships to facilitate fast, efficient transition across the drug discovery and development pipeline through to Proof of Concept studies in man.

Please click here for the company factsheet